3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled